Caribou Biosciences (CRBU) Competitors $1.80 -0.01 (-0.55%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CRBU vs. ABUS, TRDA, PRTA, TECX, CRGX, STOK, ALT, EXAI, TERN, and ORICShould you be buying Caribou Biosciences stock or one of its competitors? The main competitors of Caribou Biosciences include Arbutus Biopharma (ABUS), Entrada Therapeutics (TRDA), Prothena (PRTA), Tectonic Therapeutic (TECX), CARGO Therapeutics (CRGX), Stoke Therapeutics (STOK), Altimmune (ALT), Exscientia (EXAI), Terns Pharmaceuticals (TERN), and ORIC Pharmaceuticals (ORIC). These companies are all part of the "pharmaceutical products" industry. Caribou Biosciences vs. Arbutus Biopharma Entrada Therapeutics Prothena Tectonic Therapeutic CARGO Therapeutics Stoke Therapeutics Altimmune Exscientia Terns Pharmaceuticals ORIC Pharmaceuticals Caribou Biosciences (NASDAQ:CRBU) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, community ranking, risk and analyst recommendations. Which has higher earnings and valuation, CRBU or ABUS? Arbutus Biopharma has lower revenue, but higher earnings than Caribou Biosciences. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCaribou Biosciences$11.48M14.20-$102.07M-$1.65-1.09Arbutus Biopharma$6.74M90.22-$72.85M-$0.43-7.47 Does the MarketBeat Community believe in CRBU or ABUS? Arbutus Biopharma received 410 more outperform votes than Caribou Biosciences when rated by MarketBeat users. Likewise, 71.03% of users gave Arbutus Biopharma an outperform vote while only 60.00% of users gave Caribou Biosciences an outperform vote. CompanyUnderperformOutperformCaribou BiosciencesOutperform Votes2460.00% Underperform Votes1640.00% Arbutus BiopharmaOutperform Votes43471.03% Underperform Votes17728.97% Does the media refer more to CRBU or ABUS? In the previous week, Arbutus Biopharma had 1 more articles in the media than Caribou Biosciences. MarketBeat recorded 2 mentions for Arbutus Biopharma and 1 mentions for Caribou Biosciences. Arbutus Biopharma's average media sentiment score of 1.48 beat Caribou Biosciences' score of 1.48 indicating that Arbutus Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caribou Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arbutus Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is CRBU or ABUS more profitable? Arbutus Biopharma has a net margin of -1,137.65% compared to Caribou Biosciences' net margin of -1,290.81%. Caribou Biosciences' return on equity of -45.46% beat Arbutus Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Caribou Biosciences-1,290.81% -45.46% -38.07% Arbutus Biopharma -1,137.65%-68.18%-51.55% Do insiders and institutionals have more ownership in CRBU or ABUS? 77.5% of Caribou Biosciences shares are held by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are held by institutional investors. 9.5% of Caribou Biosciences shares are held by insiders. Comparatively, 4.0% of Arbutus Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more risk and volatility, CRBU or ABUS? Caribou Biosciences has a beta of 2.27, meaning that its share price is 127% more volatile than the S&P 500. Comparatively, Arbutus Biopharma has a beta of 1.84, meaning that its share price is 84% more volatile than the S&P 500. Do analysts prefer CRBU or ABUS? Caribou Biosciences presently has a consensus price target of $10.20, indicating a potential upside of 466.67%. Arbutus Biopharma has a consensus price target of $5.50, indicating a potential upside of 71.34%. Given Caribou Biosciences' higher probable upside, research analysts clearly believe Caribou Biosciences is more favorable than Arbutus Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Caribou Biosciences 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Arbutus Biopharma 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryCaribou Biosciences and Arbutus Biopharma tied by winning 8 of the 16 factors compared between the two stocks. Ad Behind the MarketsWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Get Caribou Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CRBU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRBU vs. The Competition Export to ExcelMetricCaribou BiosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$163.00M$2.94B$5.12B$9.07BDividend YieldN/A1.90%4.91%4.22%P/E Ratio-1.0946.7391.3417.19Price / Sales14.20411.851,116.63116.80Price / CashN/A182.1042.5837.86Price / Book0.433.894.794.78Net Income-$102.07M-$42.21M$120.07M$225.60M7 Day Performance-5.76%-2.14%-1.90%-1.24%1 Month Performance-9.09%4.21%11.43%3.06%1 Year Performance-70.83%18.40%30.59%16.50% Caribou Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRBUCaribou Biosciences2.2028 of 5 stars$1.80-0.6%$10.20+466.7%-69.4%$163.00M$11.48M-1.09100ABUSArbutus Biopharma2.5545 of 5 stars$3.59+3.2%$5.50+53.2%+45.2%$680.27M$18.14M-8.0973Positive NewsTRDAEntrada Therapeutics2.8936 of 5 stars$18.15+2.8%$25.67+41.4%+17.3%$679.17M$129.01M11.11110Positive NewsGap DownPRTAProthena1.6269 of 5 stars$12.60-1.5%$61.83+390.7%-58.8%$677.99M$133.35M-5.16173Analyst ForecastNews CoverageTECXTectonic Therapeutic2.9329 of 5 stars$45.81+1.1%$72.25+57.7%N/A$675.84MN/A-7.70120CRGXCARGO Therapeutics1.4673 of 5 stars$14.17+3.1%$31.80+124.4%-20.0%$652.22MN/A-3.23116STOKStoke Therapeutics4.1914 of 5 stars$12.31+2.1%$20.83+69.2%+140.1%$652.06M$8.78M-5.74100Analyst ForecastNews CoverageGap DownALTAltimmune1.9539 of 5 stars$9.05+0.2%$20.00+121.0%+3.4%$643.68M$52,000.00-5.8350News CoveragePositive NewsEXAIExscientia1.0682 of 5 stars$4.84+3.2%$7.00+44.6%-20.8%$632.93M$25.60M-3.21280High Trading VolumeTERNTerns Pharmaceuticals4.2382 of 5 stars$6.94+3.1%$18.30+163.7%-6.8%$589.48M$1M-5.7040ORICORIC Pharmaceuticals3.6817 of 5 stars$8.25-3.2%$18.29+121.6%-3.8%$582.20MN/A-4.6880Insider TradeGap Down Related Companies and Tools Related Companies Arbutus Biopharma Competitors Entrada Therapeutics Competitors Prothena Competitors Tectonic Therapeutic Competitors CARGO Therapeutics Competitors Stoke Therapeutics Competitors Altimmune Competitors Exscientia Competitors Terns Pharmaceuticals Competitors ORIC Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CRBU) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Caribou Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Caribou Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
